0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Acute Myeloid Leukemia (AML)-Epidemiology Forecast to 2028
Published Date: February 2019
|
Report Code: DELV-Epid-41
Home | Market Reports | Health | Health Conditions | Cancer
Acute Myeloid Leukemia Epidemiology Forecast to 2028

Acute Myeloid Leukemia (AML)-Epidemiology Forecast to 2028

Code: DELV-Epid-41
Report
February 2019
50 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures

DelveInsight's "Acute Myeloid Leukemia (AML) - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Acute Myeloid Leukemia (AML) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Acute Myeloid Leukemia (AML) Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Acute Myeloid Leukemia (AML) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Acute Myeloid Leukemia (AML) outlook. It also includes the explanation of changing trends of epidemiology outlining the Acute Myeloid Leukemia (AML) scenario.

Acute Myeloid Leukemia (AML) Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Acute Myeloid Leukemia (AML) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Acute Myeloid Leukemia (AML) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Acute Myeloid Leukemia (AML) Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Acute Myeloid Leukemia (AML)

Key assessments
• Patient Segmentation in Acute Myeloid Leukemia (AML)
• Acute Myeloid Leukemia (AML) Risk & Burden
• Factors driving growth in a specific Acute Myeloid Leukemia (AML) patient population

  1. Report Introduction
    2. Acute Myeloid Leukemia (AML) Epidemiology Overview at a Glance
    2.1. Patient Share Distribution of Acute Myeloid Leukemia (AML) in 2016
    2.2. Patient Share Distribution of Acute Myeloid Leukemia (AML) in 2028
    3. Disease Background and Overview: Acute Myeloid Leukemia (AML)
    3.1. Introduction
    3.2. Symptoms
    3.3. Etiology
    3.4. Risk Factors
    3.5. Pathophysiology
    3.6. Diagnosis
    3.7. Treatment
    4. Epidemiology and Patient Population
    4.1. Key Findings
    4.2. Total Prevalent/ Incident Patient Population of Acute Myeloid Leukemia (AML) in 7MM
    4.3. Total Prevalent/ Incident Patient Population of Acute Myeloid Leukemia (AML) in 7MM – By Countries
    5. Epidemiology of Acute Myeloid Leukemia (AML) by Countries
    5.1. United States
    5.1.1. Assumptions and Rationale
    5.1.2. Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML)
    5.1.3. Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) *
    5.1.4. Sex- Specific Cases of the Acute Myeloid Leukemia (AML)*
    5.1.5. Diagnosed Cases of the Acute Myeloid Leukemia (AML)
    5.2. EU5
    5.3. Assumptions and Rationale
    5.4. Germany
    5.4.1. Assumptions and Rationale
    5.4.2. Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML)
    5.4.3. Sub-Type Specific cases of the Acute Myeloid Leukemia (AML)*
    5.4.4. Sex- Specific Cases of the Acute Myeloid Leukemia (AML)*
    5.4.5. Diagnosed Cases of the Acute Myeloid Leukemia (AML)
    5.5. France
    5.5.1. Assumptions and Rationale
    5.5.2. Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML)
    5.5.3. Sub-Type Specific cases of the Acute Myeloid Leukemia (AML)*
    5.5.4. Sex- Specific Cases of the Acute Myeloid Leukemia (AML)*
    5.5.5. Diagnosed Cases of the Acute Myeloid Leukemia (AML)
    5.6. Italy
    5.6.1. Assumptions and Rationale
    5.6.2. Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML)
    5.6.3. Sub-Type Specific cases of the Acute Myeloid Leukemia (AML)*
    5.6.4. Sex- Specific Cases of the Acute Myeloid Leukemia (AML)*
    5.6.5. Diagnosed Cases of the Acute Myeloid Leukemia (AML)
    5.7. Spain
    5.7.1. Assumptions and Rationale
    5.7.2. Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML)
    5.7.3. Sub-Type Specific cases of the Acute Myeloid Leukemia (AML)*
    5.7.4. Sex- Specific Cases of the Acute Myeloid Leukemia (AML)*
    5.7.5. Diagnosed Cases of the Acute Myeloid Leukemia (AML)
    5.8. United Kingdom
    5.8.1. Assumptions and Rationale
    5.8.2. Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML)
    5.8.3. Sub-Type Specific cases of the Acute Myeloid Leukemia (AML)*
    5.8.4. Sex- Specific Cases of the Acute Myeloid Leukemia (AML)*
    5.8.5. Diagnosed Cases of the Acute Myeloid Leukemia (AML)
    5.9. Japan
    5.9.1. Assumptions and Rationale
    5.9.2. Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML)
    5.9.3. Sub-Type Specific cases of the Acute Myeloid Leukemia (AML)*
    5.9.4. Sex- Specific Cases of the Acute Myeloid Leukemia (AML)*
    5.9.5. Diagnosed Cases of the Acute Myeloid Leukemia (AML)
    6. Unmet Needs of the Acute Myeloid Leukemia (AML)
    7. Appendix
    8. Report Methodology
    8.1. Sources
    9. DelveInsight Capabilities
    10. Disclaimer
    11. About DelveInsight
    *Indication Specific

List of Tables

Table 1: Total Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in 7MM
Table 2: Total Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in United States (2016-2028)*
Table 6: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in France (2016-2028) *
Table 13: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in France (2016-2028) *
Table 14: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in UK (2016-2028) *
Table 26: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in Japan (2016-2028)


List of Figures

Figure 1: Total Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in France (2016-2028) *
Figure 14: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in Japan (2016-2028)

SELECT A FORMAT
Added to Cart

Electronic (PDF)
$3250
This license allows only one user to access the PDF.

Electronic (PDF)
$6500
This license allows all the users of an enterprise residing in one location to access the PDF

Electronic (PDF)
$9750
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Nano Dimension

RELATED REPORTS

China Chemotheraphy Induced Nausea and Vomitting CINV Drugs Market Report Forecast 2021 2027
China Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Report & Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-18X6955
Mon Oct 25 00:00:00 UTC 2021

Add to Cart

China Chemotherapy Induced Nausea and Vomiting CINV Drugs Market Report Forecast 2021 2027
China Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Report & Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-28V6728
Mon Oct 25 00:00:00 UTC 2021

Add to Cart

China Anti inflammatory Therapeutics Market Report Forecast 2021 2027
China Anti-inflammatory Therapeutics Market Report & Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-4J2573
Sat Oct 02 00:00:00 UTC 2021

Add to Cart

China Anti tumor Drug Market Report Forecast 2021 2027
China Anti-tumor Drug Market Report & Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-27N2168
Sat Oct 02 00:00:00 UTC 2021

Add to Cart